关于（-）司来吉兰临床药理学的近期观察 - Suppr

Suppr

超能文献

Recent observations on the clinical pharmacology of (-)deprenyl.

作者信息

Stern G M, Lees A J, Sandler M

出版信息

J Neural Transm. 1978;43(3-4):245-51. doi: 10.1007/BF01246961.

DOI:10.1007/BF01246961

PMID:745017

Abstract

摘要

相似文献

Recent observations on the clinical pharmacology of (-)deprenyl.关于（-）司来吉兰临床药理学的近期观察

J Neural Transm. 1978;43(3-4):245-51. doi: 10.1007/BF01246961.

(-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease.（-）-司来吉兰可延长帕金森病患者左旋多巴的疗效。

Mod Probl Pharmacopsychiatry. 1983;19:170-6. doi: 10.1159/000407513.

L-deprenyl in the treatment of Parkinson's disease.左旋司来吉兰治疗帕金森病

J Neural Transm Suppl. 1983;19:283-90.

Deprenyl (selegiline) in the treatment of Parkinson's disease.司来吉兰治疗帕金森病

Acta Neurol Scand Suppl. 1983;95:107-11. doi: 10.1111/j.1600-0404.1983.tb01523.x.

(-)Deprenyl in the treatment of Parkinson's disease.（-）司来吉兰治疗帕金森病。

Clin Neuropharmacol. 1982;5(2):195-230. doi: 10.1097/00002826-198205020-00004.

Long term treatment with L-deprenyl.用L-司来吉兰进行长期治疗。

J Neural Transm. 1978;43(3-4):239-44. doi: 10.1007/BF01246960.

L-deprenyl treatment of on-off phenomena in Parkinson's disease.

J Neural Transm. 1978;43(3-4):253-62. doi: 10.1007/BF01246962.

Deprenyl in Parkinson's disease.

Lancet. 1982 Sep 25;2(8300):695-6.

R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.R-(-)-司来吉兰作为左旋多巴治疗帕金森病的辅助药物。

J Neural Transm Suppl. 1987;25:149-55.

Deprenyl (selegiline) in combination treatment of Parkinson's disease.

Acta Neurol Scand Suppl. 1983;95:123-6. doi: 10.1111/j.1600-0404.1983.tb01526.x.

引用本文的文献

How to Optimize the Effectiveness and Safety of Parkinson's Disease Therapy? - A Systematic Review of Drugs Interactions with Food and Dietary Supplements.如何优化帕金森病治疗的效果和安全性？——药物与食物和膳食补充剂相互作用的系统评价。

Curr Neuropharmacol. 2022;20(7):1427-1447. doi: 10.2174/1570159X19666211116142806.

Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.司来吉兰（丙炔苯丙胺）治疗帕金森病的安全性。

Drug Saf. 1998 Jul;19(1):11-22. doi: 10.2165/00002018-199819010-00002.

Drug-induced sleep disturbances. Focus on nonpsychotropic medications.药物引起的睡眠障碍。聚焦于非精神药物。

Drug Saf. 1997 Feb;16(2):133-49. doi: 10.2165/00002018-199716020-00005.

Treatment of Parkinson's disease: problems with a progressing disease.帕金森病的治疗：进展性疾病的问题

J Neural Transm. 1981;51(1-2):161-74. doi: 10.1007/BF01664013.

The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties.（-）-司来吉兰的苯丙胺代谢产物对其抗帕金森病特性的作用。

J Neural Transm. 1982;54(1-2):105-10. doi: 10.1007/BF01249283.

Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinsons's disease.司来吉兰是一种用于帕金森病长期治疗的脑单胺氧化酶B（MAO-B）选择性抑制剂。

Br J Clin Pharmacol. 1980 Jan;9(1):98-9. doi: 10.1111/j.1365-2125.1980.tb04805.x.

Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease.司来吉兰对阿尔茨海默病患者脑脊液单胺代谢产物的剂量依赖性效应。

Psychopharmacology (Berl). 1987;91(3):293-6. doi: 10.1007/BF00518180.

The neuropharmacological profile of N-methyl-N-propargyl-2-aminotetralin: a potent monoamine oxidase inhibitor.N-甲基-N-炔丙基-2-氨基四氢萘的神经药理学特性：一种强效单胺氧化酶抑制剂。

Naunyn Schmiedebergs Arch Pharmacol. 1985 Jul;330(1):50-8. doi: 10.1007/BF00586709.

Selegiline and Parkinson's disease. Protective and symptomatic considerations.

Drugs. 1990 May;39(5):646-51. doi: 10.2165/00003495-199039050-00002.

Absence of "cheese effect" during deprenyl therapy: some recent studies.司来吉兰治疗期间“奶酪效应”的缺失：一些近期研究

J Neural Transm. 1978;43(3-4):209-15. doi: 10.1007/BF01246957.

本文引用的文献

Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard.对《人类受试者睡眠阶段标准化术语、技术和评分系统手册》（ Rechtschaffen和Kales，1968年标准）的拟议补充和修订。

Psychiatry Clin Neurosci. 2001 Jun;55(3):305-10. doi: 10.1046/j.1440-1819.2001.00810.x.

Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor.拟交感神经胺与一种新型单胺氧化酶抑制剂之间的相互作用。

Psychopharmacologia. 1970 Aug 19;18(1):118-23. doi: 10.1007/BF00402391.

The role of monoamines and acetylcholine-containing neurons in the regulation of the sleep-waking cycle.单胺能和胆碱能神经元在睡眠-觉醒周期调节中的作用。

Ergeb Physiol. 1972;64:166-307. doi: 10.1007/3-540-05462-6_2.

The clinical physiology of side effects in long-term L-DOPA therapy.长期左旋多巴治疗中副作用的临床生理学

Adv Neurol. 1974;5:347-365.

The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.单胺氧化酶-B抑制剂司立吉林增强左旋多巴治疗后的抗运动不能作用。

J Neural Transm. 1975;36(3-4):303-26. doi: 10.1007/BF01253131.

Deprenyl is metabolized to methamphetamine and amphetamine in man.在人体中，司来吉兰会代谢为甲基苯丙胺和苯丙胺。

Br J Clin Pharmacol. 1978 Dec;6(6):542-4. doi: 10.1111/j.1365-2125.1978.tb00883.x.

Deprenil: loss of selectivity for inhibition of B-type MAO after repeated treatment.司来吉兰：重复治疗后对B型单胺氧化酶抑制作用的选择性丧失。

Biochem Pharmacol. 1978 Mar 1;27(5):801-2. doi: 10.1016/0006-2952(78)90525-7.

Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'.

Psychopharmacology (Berl). 1978 Apr 14;57(1):33-8. doi: 10.1007/BF00426954.

Deprenyl in Parkinson's disease.

Lancet. 1977 Oct 15;2(8042):791-5. doi: 10.1016/s0140-6736(77)90725-5.

Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.“美多芭”与左旋司来吉兰联合治疗帕金森病的意义。一项长期研究。

Lancet. 1977 Feb 26;1(8009):439-43. doi: 10.1016/s0140-6736(77)91940-7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验